No Data
Precision BioSciences to Present Preclinical Data on Hepatitis B Treatment at EASL Congress
Precision BioSciences, Inc. (NASDAQ:DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies, today announced that the company w
Express News | Precision Biosciences presented new clinical safety data for Pbgene-Hbv candidate at the European Liver Research Association Conference.
Express News | Precision BioSciences Inc: Ind and/or Cta on-Track for Submission in 2024
Express News | Precision BioSciences Inc: Pbgene-Hbv Was Well Tolerated Across Multiple Administrations With No off-Target Editing Observed
Express News | Precision BioSciences Presents New Preclinical Safety Data for Pbgene-Hbv Clinical Candidate at the European Association for the Study of the Liver Congress
HC Wainwright & Co. : The Precision BioSciences (DTIL.US) rating was reaffirmed, adjusted from buy to buy rating, and the target price was adjusted from $60.00 to $60.00.
HC Wainwright & Co. : The Precision BioSciences (DTIL.US) rating was reaffirmed, adjusted from buy to buy rating, and the target price was adjusted from $60.00 to $60.00.